ImmuCell (ICCC) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
13 Nov, 2026Executive summary
Q3 product sales rose 46.0% YoY to $8.040M; net income was $953K versus a $140K loss, driven by First Defense® volume, portfolio expansion and pricing.
9M sales grew 27.8% to $25.584M; net income increased to $4.729M from $1.809M, including a non-recurring $2.0M settlement.
Distributor out-the-door volume rose 18% YoY; broader commercial activity and manufacturing execution supported growth.
Financial highlights
Q3 product sales were $8.040M versus $5.506M; 9M sales were $25.584M versus $20.018M.
Q3 operating income was $958K versus $20K; 9M operating income was $4.862M versus $1.707M, including $2.0M of other operating income.
Q3 net income was $953K versus a $140K loss; 9M net income was $4.729M versus $1.809M, including the $2.0M settlement.
Adjusted EBITDA was $1.884M in Q3 versus $750K; 9M adjusted EBITDA was $7.289M versus $4.420M.
Sept. 30 cash was $7.91M and net working capital was $16.90M, versus $3.81M and $12.97M at Dec. 31, 2025.
Outlook and guidance
First Defense® capacity expansion remains targeted for completion in H1 2027 for freeze-drying and year-end 2027 for liquids processing, within the original $8M budget.
The expansion requires $6.3M of additional spending as of Sept. 30, 2026; management expects the project to finish on time and within budget.
Yield improvements are expected to support demand until added drying capacity comes online; the new freeze dryer is expected to roughly triple freeze-drying capacity.
Strong calf values are expected to continue through 2027 and 2028; Functional Feed met full-year targets early.
Latest events from ImmuCell
- First Defense gains share as sales rebound and capacity expansion targets 3x output.ICCC
Investor presentation - Strong growth, market share gains, and financial recovery position First Defense® for expansion.ICCC
Investor presentation - Q2 2026 net income jumped to $1.8M on 11.5% sales growth and a $2M legal settlement.ICCC
Q2 2026 - Record sales and margin growth position First Defense® for continued market share gains.ICCC
Investor presentation - All proposals passed and a major manufacturing expansion was announced to support growth.ICCC
AGM 2026 - First Defense® gains share in a growing market, fueling record sales and margin expansion.ICCC
Investor presentation - Record Q1 2026 sales and net income growth fueled by margin gains and strong cash flow.ICCC
Q1 2026 - Full-year sales up 4.3% as Tri-Shield® growth and First Defense® focus offset declines.ICCC
Q4 2025 TU - Record Q1 sales, margin gains, and net income highlight strong growth and operational recovery.ICCC
Q1 2025